Orthofix Medical INC

Orthofix Medical Inc. announced that CMS has reversed recent changes to Medicare reimbursement for non-invasive bone growth stimulators, returning rates to pre-May 18, 2026 levels.

Orthofix Medical Inc. shareholders approved an amendment to the stock purchase plan, increasing available shares, and re-elected the board of directors at the 2026 Annual Meeting.

Orthofix Medical Inc. revises its 2026 financial outlook downwards due to anticipated declines in Medicare reimbursement for non-invasive bone growth stimulators.

Orthofix Medical Inc. announced its first quarter 2026 financial results, showing steady execution and reaffirming its full-year financial guidance.

Orthofix Medical Inc. announced preliminary Q1 2026 net sales of $196.7 million, a 1.6% increase, and reaffirmed its full-year 2026 guidance, alongside a strategic realignment of its Spine leadership team.

Orthofix Medical Inc. announced robust fourth quarter and full-year 2025 financial results, driven by strong performance in Bone Growth Therapies and U.S. Limb Reconstruction, alongside an optimistic 2026 financial guidance and updated three-year targets.

Orthofix Medical Inc. reported Q1 2026 net sales of $196.7 million, a 1.6% increase year-over-year, driven by growth in Global Limb Reconstruction and Therapeutic Solutions, while navigating significant legal settlements.

Orthofix Medical Inc. reported increased net sales and a narrower net loss in Q3 2025, driven by growth in Global Orthopedics and Bone Growth Therapies, despite significant legal expenses and the discontinuation of M6 product lines.

Orthofix Medical Inc. reported a significantly reduced net loss and positive free cash flow for Q2 2025, driven by sales growth and improved operational efficiency, despite ongoing legal challenges and the impairment of its M6 product lines.

Orthofix Medical Inc. reports a net loss for Q1 2025, influenced by the discontinuation of its M6 product line, while highlighting growth in other segments.

Orthofix Medical Inc. saw a 7% increase in net sales in the third quarter of 2024 and secured a new $275 million credit facility.

Orthofix Medical Inc. announced a 6% increase in net sales for the second quarter of 2024, driven by strong growth in Bone Growth Therapies and U.S. Spine Fixation.

Orthofix Medical Inc. reported 2025 net sales of $822.3 million, a 2.9% increase, alongside strategic discontinuation of M6 artificial disc product lines and ongoing legal proceedings involving former executives.

Orthofix Medical Inc.'s 2024 10-K filing reveals a 7.1% increase in net sales, driven by growth in key segments, while navigating ongoing integration efforts and strategic realignments.

Orthofix Medical Inc. released its 10-K filing, highlighting a significant increase in net sales and strategic advancements in its Global Spine and Global Orthopedics segments for the year ended December 31, 2023.

Orthofix Medical Inc. director Alan Lee Bazaar has been granted 14,965 deferred stock units as part of his compensation.

Director Charles R. Kummeth was granted 14,965 deferred stock units by Orthofix Medical Inc. as part of an equity award.

Orthofix Medical Inc. director Jason Hannon was granted 14,965 deferred stock units as part of an equity compensation award.

Orthofix Medical Inc. director Michael Finegan acquired 20,721 deferred stock units as part of an equity compensation award.

Orthofix Medical Inc. director Vickie L. Capps was granted 14,965 deferred stock units as part of an equity compensation award.

Director John B. Henneman III was granted 14,965 deferred stock units by Orthofix Medical Inc. as part of an equity award.

Orthofix Medical Inc. has issued its 2026 Proxy Statement detailing the upcoming Annual Meeting of Shareholders on June 10, 2026, outlining proposals for director elections, executive compensation, auditor ratification, and stock purchase plan amendments.

Orthofix Medical Inc. will hold its annual shareholder meeting on June 18, 2025, to vote on director elections, executive compensation, and the ratification of Ernst & Young LLP as the independent auditor.

Orthofix Medical Inc. will hold its 2025 Annual Meeting of Shareholders on June 18, 2025, to elect directors, approve executive compensation, and ratify the appointment of Ernst & Young as its independent accounting firm.

Orthofix is requesting shareholder approval to increase the number of shares available under its 2012 Long-Term Incentive Plan by 5,000,000 shares to attract, retain, and motivate employees.

Orthofix Medical Inc. will hold its annual shareholders meeting on June 19, 2023, with several key proposals up for vote, including the election of directors and amendments to the certificate of incorporation and incentive plans.

Orthofix Medical Inc. has released its proxy statement detailing proposals for the upcoming 2024 Annual Meeting of Shareholders, including director elections, executive compensation, and amendments to incentive plans.

Juniper Investment Company and affiliated entities have disclosed beneficial ownership of approximately 11% of Orthofix Medical Inc.'s outstanding common stock.

Juniper Investment Company and its affiliates have increased their beneficial ownership in Orthofix Medical Inc. to 9.6% through recent open market purchases.

Juniper Investment Company and its affiliates have increased their beneficial ownership in Orthofix Medical Inc. to 8.2% through recent open market purchases.

Juniper Investment Company and its affiliates have increased their beneficial ownership in Orthofix Medical Inc. to 7.2% through recent open market purchases.

Engine Capital and its affiliated entities have significantly increased their beneficial ownership in Orthofix Medical Inc., now holding an aggregate of 10.9% of the common stock.

Juniper Investment Company and its affiliated funds have significantly increased their beneficial ownership in Orthofix Medical Inc., now holding 6.1% of the common stock through recent open market purchases.

Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 2,700,000 shares, representing 6.73% of Orthofix Medical Inc.'s common stock, as of March 31, 2026.

The Vanguard Group has updated its beneficial ownership in Orthofix Medical Inc. to 0% following an internal corporate realignment.

Armistice Capital, LLC and Steven Boyd reported a 5.65% beneficial ownership stake in Orthofix Medical Inc., totaling 2,236,000 common shares.

Armistice Capital, LLC and Steven Boyd have disclosed a 7.54% beneficial ownership stake in Orthofix Medical Inc., holding 2,978,000 shares.

Armistice Capital, LLC and Steven Boyd have disclosed a 7.56% beneficial ownership stake in Orthofix Medical Inc., holding 2,964,000 shares of common stock.

BlackRock, Inc. has filed an Amendment No. 5 to Schedule 13G, reporting a beneficial ownership of 7.7% in Orthofix Medical Inc. as of March 31, 2025.